Loading...
Loading...
BioTime
BTX, an Alameda-based company engaged in research
and development of innovative new products in the field of regenerative
medicine utilizing stem cells and related technology, announced today that it
has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to
pursue opportunities and acquire assets and businesses in the fields of stem
cells and regenerative medicine. Thomas Okarma, PhD, MD, will serve as the
Chief Executive Officer and as a member of the board of directors of BioTime's
new subsidiary. Dr. Okarma is the former President and Chief Executive Officer
of Geron Corporation and served on that company's board of directors.
Since 2010, BioTime has expanded the scope of its business through strategic
acquisitions and has been continually exploring other acquisition
opportunities in its fields of interest. BioTime's strategic acquisitions
include:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsManagement
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in